| Trends in prescription drug launch prices, 2008-2021 BN Rome, AC Egilman, AS Kesselheim JAMA 327 (21), 2145-2147, 2022 | 83 | 2022 |
| Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis JD Wallach, AC Egilman, SS Dhruva, ME McCarthy, JE Miller, S Woloshin, ... bmj 361, 2018 | 73 | 2018 |
| Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease JD Wallach, S Serghiou, L Chu, AC Egilman, V Vasiliou, JS Ross, ... BMC medical research methodology 20, 1-10, 2020 | 48 | 2020 |
| Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022 BN Rome, S Nagar, AC Egilman, J Wang, WB Feldman, AS Kesselheim JAMA Health Forum 4 (1), e225218-e225218, 2023 | 36 | 2023 |
| Transparency of regulatory data across the European medicines agency, health Canada, and US food and Drug Administration AC Egilman, A Kapczynski, ME McCarthy, AT Luxkaranayagam, ... Journal of Law, Medicine & Ethics 49 (3), 456-485, 2021 | 30 | 2021 |
| Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration J Puthumana, AC Egilman, AD Zhang, JL Schwartz, JS Ross JAMA Internal Medicine 181 (4), 559-560, 2021 | 29 | 2021 |
| Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences JD Wallach, AC Egilman, AD Gopal, N Swami, HM Krumholz, JS Ross Research integrity and peer review 3, 1-8, 2018 | 26 | 2018 |
| Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk L Chu, JPA Ioannidis, AC Egilman, V Vasiliou, JS Ross, JD Wallach International journal of epidemiology 49 (2), 608-618, 2020 | 21 | 2020 |
| Added therapeutic benefit of top-selling brand-name drugs in Medicare AC Egilman, BN Rome, AS Kesselheim JAMA 329 (15), 1283-1289, 2023 | 20 | 2023 |
| Timeliness of postmarket studies for new pharmaceuticals approved between 2009 and 2012: a cross-sectional analysis JD Wallach, AC Egilman, JS Ross, S Woloshin, LM Schwartz Journal of General Internal Medicine 34, 492-495, 2019 | 18 | 2019 |
| Evaluation of trials comparing single-enantiomer drugs to their racemic precursors: A systematic review AS Long, AD Zhang, CE Meyer, AC Egilman, JS Ross, JD Wallach JAMA Network Open 4 (5), e215731-e215731, 2021 | 16 | 2021 |
| Spending by the Centers for Medicare & Medicaid Services before and after confirmation of benefit for drugs granted US Food and Drug Administration accelerated approval, 2012 … JJ Skydel, AC Egilman, JD Wallach, R Ramachandran, R Gupta, JS Ross JAMA Health Forum 3 (5), e221158-e221158, 2022 | 14 | 2022 |
| Medicare spending and potential savings on brand-name drugs with available generic substitutes excluded by 2 large pharmacy benefit managers, 2012 through 2015 AC Egilman, JD Wallach, JS Ross, SS Dhruva JAMA Internal Medicine 178 (4), 567-569, 2018 | 12 | 2018 |
| Confidentiality orders and public interest in drug and medical device litigation AC Egilman, AS Kesselheim, HM Krumholz, JS Ross, J Kim, A Kapczynski JAMA Internal Medicine 180 (2), 292-299, 2020 | 9 | 2020 |
| Medicare Part D spending on single-enantiomer drugs versus their racemic precursors AC Egilman, AD Zhang, JD Wallach, JS Ross Annals of internal medicine 171 (7), 521-523, 2019 | 7 | 2019 |
| Using multiple authorized generics to maintain high prices: the example of entacapone BN Rome, AC Egilman, NG Patel, AS Kesselheim Value in Health 26 (3), 370-377, 2023 | 6 | 2023 |
| Frequency of approval and marketing of biosimilars with a skinny label and associated Medicare savings AC Egilman, VL Van de Wiele, BN Rome, JJ Darrow, SS Tu, ... JAMA Internal Medicine 183 (1), 82-84, 2023 | 6 | 2023 |
| Optimizing the data available via Health Canada’s clinical information portal AC Egilman, JS Ross, M Herder CMAJ 193 (33), E1305-E1306, 2021 | 6 | 2021 |
| Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis AC Egilman, AS Kesselheim, J Avorn, AJN Raymakers, BN Rome JAMA dermatology 160 (4), 409-416, 2024 | 5 | 2024 |
| Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017 AC Egilman, JD Wallach, CJ Morten, P Lurie, JS Ross Research Integrity and Peer Review 4, 1-8, 2019 | 5 | 2019 |
Joseph S. RossYale UniversityOverená e-mailová adresa na: yale.edu